Physician profile
Alyssa Frey
NPI 1801356027
$3,741.18
in general payments reported to CMS, 2019-2025
37 companies · $694 in 2025
The $694 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $871 · 2023: $740 · 2024: $788 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $856.48 | 2021-2025 | |
| Novo Nordisk INC | $626.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $359.99 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Esperion Therapeutics, INC. | $205.48 | 2021-2023 | Nexletol |
| Amgen INC. | $175.38 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $151.71 | 2022-2025 | |
| Mannkind Corporation | $147.61 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $118.90 | 2021-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $114.58 | 2023-2025 | Rexulti |
| Dexcom, INC. | $114.32 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Bayer Healthcare Pharmaceuticals INC. | $84.87 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.02 | 2021-2024 | Xifaxan |
| Insulet Corporation | $64.53 | 2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.51 | 2022 | |
| Idorsia Pharmaceuticals US INC | $55.54 | 2023-2024 | Quviviq |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.95 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.86 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $36.55 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $27.44 | 2022 | |
| Merck Sharp & Dohme LLC | $27.22 | 2023 | Dificid |
| Averitas Pharma INC. | $26.67 | 2025 | Qutenza |
| Beta Bionics, INC. | $24.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Biogen, INC. | $24.70 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.69 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.76 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.39 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.85 | 2024 | Voquezna |
| Medtronic, INC. | $22.28 | 2025 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $20.76 | 2024 | Trintellix |
| Vifor Pharma, INC. | $18.60 | 2023 | Veltassa |
| Acella Pharmaceuticals, LLC | $17.20 | 2025 | NP Thyroid 60 |
| Paratek Pharmaceuticals, INC. | $15.53 | 2025 | Xhance, Nuzyra |
| Lundbeck LLC | $15.45 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $14.23 | 2021 | |
| Astellas Pharma US INC | $13.72 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.19 | 2021 | |
| Sumitomo Pharma America, INC. | $10.20 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.